News Conference News ACC 2025 By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE Michael O'Riordan March 31, 2025
News Conference News ACC 2024 Telemedicine Strategy After MI Scores a Win in TELE-ACS Caitlin E. Cox April 12, 2024
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2023 Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies Caitlin E. Cox February 23, 2023
News Conference News ACC 2022 Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough Michael O'Riordan April 04, 2022
News Conference News ACC 2021 SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal L.A. McKeown May 16, 2021
News Conference News ACC 2021 Low 1-Year Stroke Risk After Commercial Watchman Use Todd Neale May 15, 2021
News Conference News ACC 2020 LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout Todd Neale April 06, 2020
News Conference News ACC 2020 New Patient-Focused TAVR Quality Score Rolling Out to US Hospitals Michael O'Riordan April 06, 2020
News Conference News ACC 2020 Colchicine Cost-effective in Canada, and Even in the US: COLCOT Caitlin E. Cox March 28, 2020
News Conference News ACC 2020 Hospital MV Surgical Volume Not Tied to TMVr Outcomes Todd Neale March 19, 2020
News Conference News ACC 2019 Myocardial Injury Often Miscoded as Type 2 MI L.A. McKeown April 02, 2019
News Conference News ACC 2018 Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis Todd Neale March 12, 2018
News Conference News ACC 2018 Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS Caitlin E. Cox March 11, 2018
News Conference News ACC 2017 MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns L.A. McKeown March 27, 2017
News Conference News ACC 2017 Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them Yael L. Maxwell March 23, 2017
News Conference News ACC 2017 Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients L.A. McKeown March 21, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2016 Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes Michael O'Riordan April 07, 2016
News Conference News ACC 2016 TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough? Shelley Wood April 03, 2016